FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Joshi Alumkal

Research Profile

Disorders

Procedures

Physiology

Signal Transduction

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Joshi J Alumkal; James G Herman
Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers.
Renee C Prins; Brooks L Rademacher; Joshi J Alumkal; Kristine M Eilers; Julie N Graff; Solange Mongoue-Tchokote; Tomasz M Beer
C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.
Natsuko Suwaki; Elsa Vanhecke; Katelyn M Atkins; Manuela Graf; Katherine Swabey; Paul H. Huang; Peter Schraml; Holger Moch; Amy Mulick Cassidy; Daniel Brewer; Bissan Al-Lazikani; Paul Workman; Johann De-Bono; Stan B Kaye; James Larkin; Martin E Gore; Charles L Sawyers; Peter Nelson; Tomasz M Beer; Hao Geng; Lina Gao; David Z Qian; Joshi J Alumkal; Gary Thomas; George V Thomas
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Joshi Alumkal (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Joshi J Alumkal; James G Herman
Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers.
Cancer discovery 2012;2(11):979-81.
2012: Renee C Prins; Brooks L Rademacher; Joshi J Alumkal; Kristine M Eilers; Julie N Graff; Solange Mongoue-Tchokote; Tomasz M Beer
C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.
Urologic oncology 2012;30(1):33-7.
2011: Natsuko Suwaki; Elsa Vanhecke; Katelyn M Atkins; Manuela Graf; Katherine Swabey; Paul H. Huang; Peter Schraml; Holger Moch; Amy Mulick Cassidy; Daniel Brewer; Bissan Al-Lazikani; Paul Workman; Johann De-Bono; Stan B Kaye; James Larkin; Martin E Gore; Charles L Sawyers; Peter Nelson; Tomasz M Beer; Hao Geng; Lina Gao; David Z Qian; Joshi J Alumkal; Gary Thomas; George V Thomas
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.
Science translational medicine 2011;3(85):85ra47.
2010: Luai Zarour; Joshi J Alumkal
Emerging therapies in castrate-resistant prostate cancer.
Current urology reports 2010;11(3):152-8.
2010: Howard I Scher; Tomasz M Beer; Celestia S Higano; Aseem Anand; Mary-Ellen Taplin; Eleni Efstathiou; Dana Elizabeth Rathkopf; Julia Shelkey; Evan Y Yu; Joshi J Alumkal; David Hung; Mohammad Hirmand; Lynn Seely; Michael J Morris; Daniel C Danila; John L Humm; Steven M Larson; Martin Fleisher; Charles L Sawyers
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Lancet 2010;375(9724):1437-46.
2010: Tomasz M Beer; Charles Ryan; Joshi J Alumkal; Christopher W Ryan; Janine Sun; Kristine M Eilers
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
Anti-cancer drugs 2010;21(4):433-8.
2010: Lina Gao; Joshi J Alumkal
Epigenetic regulation of androgen receptor signaling in prostate cancer.
Epigenetics : official journal of the DNA Methylation Society 2010;5(2):100-4.
2010: Troy Dillard; Christine G (Chris) Yedinak; Joshi J Alumkal; Maria Fleseriu
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.
Pituitary 2010;13(1):29-38.
2009: Joshi J Alumkal
Through the looking glass.
Blood 2009;114(16):3363-4.
2009: Angela Gibbs; Jacob Schwartzman; Vivianne Deng; Joshi J Alumkal
Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(39):16663-8.
2008: Joshi J Alumkal; Zhe Zhang; Elizabeth B Humphreys; Christina Bennett; Leslie A Mangold; Michael A Carducci; Alan W Partin; Elizabeth Garrett-Mayer; Angelo M DeMarzo; James G Herman
Effect of DNA methylation on identification of aggressive prostate cancer.
Urology 2008;72(6):1234-9.
2008: Katy Van Hook; Joshi J Alumkal; Charles D Lopez
hADA2a and hADA3: new players in beta-catenin signaling.
Cancer biology & therapy 2008;7(1):129-30.
2004: Joshi J Alumkal; Michael A Carducci
Early use of chemotherapy in conjunction with radical prostatectomy.
Clinical prostate cancer 2004;3(3):144-9.
1999: Joshi J Alumkal; Lawrence Rice; H Vempathy; J J McCarthy; S A Riggs
Surgery-associated factor VIII inhibitors in patients without hemophilia.
The American journal of the medical sciences 1999;318(5):350-2.